Trial Profile
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Givosiran (Primary)
- Indications Acute intermittent porphyria; Aminolevulinate dehydrase deficiency porphyria; Hepatic-porphyria; Hereditary coproporphyria; Variegate-porphyria
- Focus Registrational; Therapeutic Use
- Acronyms ENVISION
- Sponsors Alnylam Pharmaceuticals
- 19 Jul 2023 Results from the 36-month final analysis of ENVISION, published in the Journal of Hepatology
- 24 Jun 2023 Results assessing long-term treatment outcomes, qualitative interviews were conducted with study participants from Phase 1/2(NCT02949830) and Phase 3 (ENVISION; NCT03338816) studies, presented at the European Association for the Study of the Liver Congress 2023.
- 04 May 2023 According to an Alnylam Pharmaceuticals media release, post-hoc analyses post-hoc analyses from this study were presented at the Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium.